• In recent weeks, Mineralys Therapeutics reported stronger-than-expected third-quarter 2025 results while advancing its lead drug lorundrostat toward a New Drug Application for uncontrolled hypertension and chronic kidney disease.
• At the same time, senior executives executed pre-arranged Rule 10b5-1 stock sales as lorundrostat gained recognition in JAMA’s Research of the Year Roundup and the company presented at the 15th Annual LifeSci Partners Corporate Access Event.
• Against this backdrop, we’ll explore how lorundrostat’s clinical progress and regulatory trajectory could influence Mineralys Therapeutics’ investment narrative.

We've found 12 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

What Is Mineralys Therapeutics' Investment Narrative?

To own Mineralys today, you really have to believe that lorundrostat can convert its growing clinical profile into a successful New Drug Application and, eventually, commercial uptake in hypertension and chronic kidney disease. The recent JAMA “Research of the Year” recognition and continued trial momentum reinforce that thesis, and the company’s presentation at the LifeSci Partners event keeps the story in front of specialists who matter. In the near term, the key catalysts still look tied to NDA timing and upcoming EXPLORE-OSA data, rather than to the recent executive stock sales, which appear to follow pre-set 10b5-1 plans and have not changed the broader investment case. That said, persistent losses, past dilution and fresh insider selling keep financing risk and alignment questions firmly on the table.

However, there is an additional financing-related risk here that investors should be aware of. Despite retreating, Mineralys Therapeutics' shares might still be trading above their fair value and there could be some more downside. Discover how much.

Exploring Other Perspectives

Four fair value estimates from the Simply Wall St Community span roughly US$40 to a very large upper bound, underscoring how far apart individual views can be. Set against this wide dispersion, the investment story still hinges on lorundrostat’s regulatory path and Mineralys’ need to fund ongoing losses, which may influence how those different expectations ultimately play out. These contrasting perspectives invite you to weigh multiple angles before forming your own view.

Explore 4 other fair value estimates on Mineralys Therapeutics - why the stock might be worth just $39.68!

Build Your Own Mineralys Therapeutics Narrative

Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Mineralys Therapeutics research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free Mineralys Therapeutics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Mineralys Therapeutics' overall financial health at a glance.

Seeking Other Investments?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
• AI is about to change healthcare. These 108 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.